» Articles » PMID: 36547011

Changes in Serum Immunoglobulin G Subclasses During the Treatment of Patients with Chronic Obstructive Pulmonary Disease with Infectious Exacerbations

Overview
Journal Adv Respir Med
Publisher MDPI
Date 2022 Dec 22
PMID 36547011
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Despite the theoretical importance of serum immunoglobulin (Ig) in the outcome of COPD exacerbations, the existing evidence for this has not been enough. This study was performed to evaluate changes in serum Ig levels and their relationship with outcomes of acute infectious exacerbations in patients with COPD. Methods: The prospective study was conducted at Military Hospital 103 from August 2017 to April 2019. Group D patients with COPD with infectious exacerbation were selected for participation in the study. The control group consisted of 30 healthy people. The patients were provided clinical examination and laboratory service; simultaneously, we measured their serum Ig levels (total IgG, IgG1, IgG2, IgG3, IgG4) at two time points: at admission (T1) and the final health outcome (T2). Results: The median levels of total IgG in patients at times T1 and T2 were significantly lower compared with those in the healthy group (1119.3 mg/dL and 1150.6 mg/dL compared with 2032.2 mg/dL) (p < 0.001). Regarding changes among IgG subclasses, the IgG1, IgG3, and IgG4 levels measured at T1 and T2 were reduced significantly compared with the control group (p < 0.05); the IgG3 levels at T1 were significantly higher than those at T2. IgG3 levels in patients with life-threatening exacerbations were significantly lower than the remaining ones (24.6 (26.8−155.5) mg/dL and 25.6 (29.5−161.2) mg/dL, respectively, p = 0.023). Conclusions: In group D patients with COPD with infectious exacerbations, there was a decrease in the serum IgG, IgG1, IgG3, and IgG4 levels. IgG3 levels were associated with the severity of COPD exacerbation.

Citing Articles

Serum immunoglobulin levels in group E of chronic obstructive pulmonary disease: insights for clinical management and immunoglobulin therapy strategies.

Hai C, Ba T, Bui Duc T, Xuan C, Manh T BMC Pulm Med. 2024; 24(1):381.

PMID: 39095819 PMC: 11297644. DOI: 10.1186/s12890-024-03185-5.


Serum Proteomic Profiling in Patients with Chronic Obstructive Pulmonary Disease.

Wu S, Huang K, Chang C, Chu X, Zhang K, Li B Int J Chron Obstruct Pulmon Dis. 2023; 18:1623-1635.

PMID: 37533772 PMC: 10392904. DOI: 10.2147/COPD.S413924.

References
1.
Said A, Esmail M, Abdel Naiem E, Zaki Z, Raouf R . Clinical outcomes of chronic obstructive pulmonary disease phenotypes. One center prospective study. Adv Respir Med. 2021; 89(4):369-377. DOI: 10.5603/ARM.a2021.0086. View

2.
Kim J, Park S, Hwang Y, Jang S, Jung K, Sim Y . Immunoglobulin G Subclass Deficiencies in Adult Patients with Chronic Airway Diseases. J Korean Med Sci. 2016; 31(10):1560-5. PMC: 4999397. DOI: 10.3346/jkms.2016.31.10.1560. View

3.
Su Y, Jalalvand F, Thegerstrom J, Riesbeck K . The Interplay Between Immune Response and Bacterial Infection in COPD: Focus Upon Non-typeable . Front Immunol. 2018; 9:2530. PMC: 6230626. DOI: 10.3389/fimmu.2018.02530. View

4.
McCullagh B, Comellas A, Ballas Z, Newell Jr J, Zimmerman M, Azar A . Antibody deficiency in patients with frequent exacerbations of Chronic Obstructive Pulmonary Disease (COPD). PLoS One. 2017; 12(2):e0172437. PMC: 5315316. DOI: 10.1371/journal.pone.0172437. View

5.
Garcia-Pachon E, Baeza-Martinez C, Ruiz-Alcaraz S, Grau-Delgado J . Prediction of three-month readmission based on haematological parameters in patients with severe COPD exacerbation. Adv Respir Med. 2021; 89(5):501-504. DOI: 10.5603/ARM.a2021.0076. View